PREECLAMPSIA IN THE FOCUS OF A PRACTITIONER'S ATTENTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Preeclampsia as a specific complication of pregnancy has been universally accepted to develop only in its second half and to be diagnosed with blood pressure ≥ 140/90 mm Hg and proteinuria > 0.3 g/day. However, the evidence-based medicine facts relied on the results of randomized multicenter trials suggest that many pathophysiological changes develop just in early pregnancy. In this connection, of particular importance is the elaboration of a predictive, preventive, personified, and partner management system for risk-group pregnant women with the basic areas of modern medicine. The paper proposes a program of prediction, prevention, and an individual approach to preeclampsia risk-group patients.

Full Text

Restricted Access

About the authors

Iraida Stepanovna SIDOROVA

I.M. Sechenov First Moscow State Medical University

MD, Professor, RAMS Corresponding Member, Honored Scientist 119991, Russia, Moscow, Trubetskaya str. 8 bld. 2

Natalya Aleksandrovna NIKITINA

I.M. Sechenov First Moscow State Medical University

Email: natnikitina@list.ru
Candidate of Medical Sciences, Associate Professor of the Chair of Obstetrics and Gynaecology № 1 119991, Russia, Moscow, Trubetskaya str. 8 bld. 2

References

  1. World Health Organization. WHO Recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva; 2011. 38 с.
  2. Anderson U.D., Olsson M.G., Kristensen K.H., Åkerström B., Hansson S.R. Review: Biochemical markers to predict preeclampsia. Placenta. 2012; 33(Suppl.): S42-7.
  3. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376(9741): 631-44.
  4. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 2010; 5: 173-92.
  5. Karumanchi S.A., Lindheimer M.D. Advances in the understanding of eclampsia. Curr. Hypertens. Rep. 2008; 10(4): 305-12.
  6. Стародубов В.И., Суханова Л.П. Репродуктивные проблемы демографического развития России. М.: Менеджер здравоохранения; 2012. 320 с. // Starodubov V.I., Suhanova L.P. Reproduktivnyie problemyi demograficheskogo razvitiya Rossii. M.: Menedzher zdravoohraneniya; 2012. 320 s.
  7. Liu S., Joseph K.S., Liston R.M., Bartholomew S., Walker M., Leon J.A. et al.; Maternal Health Study Group of Canadian Perinatal Surveillance System (Public Health Agency of Canada). Incidence, risk factors, and associated complications of eclampsia. Obstet. Gynecol. 2011; 118(5): 987-94.
  8. Uzan J., Carbonnel M., Piconne О., Asmar R., Ayoubi J.-M. Pre-eclampsia: pathophysiology, diagnosis and management. Vasc. Health Risk Manag. 2011; 7: 467-74.
  9. Redman C.W., Sargent I.L. Immunology of pre-eclampsia. Am. J. Reprod. Immunol. 2010; 63(6): 534-43.
  10. Сухих Г.Т., Мурашко Л.Е., ред. Преэклампсия: руководство. М.: ГЭОТАР-Медиа; 2010. 576 с. // Suhih G.T., Murashko L.E., red. Preeklampsiya: rukovodstvo. M.: GEOTAR-Media; 2010. 576 s.
  11. Dekker G., Robillard P.Y., Roberts C. The etiology of preeclampsia: the role of the father. J. Reprod. Immunol. 2011; 89(2): 126-32.
  12. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am. J. Obstet. Gynecol. 2011; 204(3): 193-201.
  13. Odibo A.O., Zhong Y., Longtine M., Tuuli M., Odibo L., Cahill A.G. et al. First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction. Placenta. 2011; 32(4): 333-8.
  14. Poon L.C., Maiz N., Valencia C., Plasencia W., Nicolaides K.H. Firsttrimester maternal serum pregnancy-associated plasma protein-A and preeclampsia. Ultrasound Obstet. Gynecol. 2009; 33(1): 23-33.
  15. Akolekar R., Syngelaki A., Beta J., Kocylowski R., Nicolaides K.H. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat. Diagn. 2009; 29(12): 1103-8.
  16. Khalil A., Cowans N.J., Spencer K., Goichman S., Meiri H., Harrington K. First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk. Ultrasound Obstet. Gynecol. 2010; 35(6): 671-9.
  17. Romero R., Kusanovic J.P., Than N.G., Erez O., Gotsch F., Espinoza J. et al. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am. J. Obstet. Gynecol. 2008; 199(2): 122. e1-122. e11.
  18. Anderson U.D., Olsson M.G., Rutardóttir S., Centlow M., Kristensen K.H., Isberg P.E. et al. Fetal hemoglobin and a1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. Am. J. Obstet. Gynecol. 2011; 204(6): 520. e1-5.
  19. Foidart J.M., Munaut C., Chantraine F., Akolekar R., Nicolaides K.H. Maternal plasma soluble endoglin at 11-13 weeks gestation in pre-eclampsia. Ultrasound Obstet. Gynecol. 2010; 35(6): 680-7.
  20. Akolekar R., Syngelaki A., Sarquis R., Zvanca M., Nicolaides K.H. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat. Diagn. 2011; 31(1): 66-74.
  21. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202(2): 161. e1-161. e11.
  22. Olsson M.G., Olofsson T., Tapper H., Akerstrom B. The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. Free Radic. Res. 2008; 42(8): 725-36.
  23. Ranta J.K., Raatikainen K., Romppanen J., Pulkki K., Heinonen S. Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(1): 48-52.
  24. Spencer K., Yu C.K., Cowans N.J., Otigbah C., Nicolaides K.H. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat. Diagn. 2005; 25(10): 949-53.
  25. Smith G.C., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 2002; 87(4): 1762-7.
  26. Goetzinger K.R., Singla A., Gerkowicz S., Dicke J.M., Gray D.L., Odibo A.O. Predicting the risk of pre-eclampsia between 11 and 13 weeks’ gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat. Diagn. 2010; 30(12-13): 1138-42.
  27. Spencer K., Cowans N.J., Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat. Diagn. 2008; 28(1): 7-10.
  28. Maynard S., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu. Rev. Med. 2008; 59: 61-78.
  29. Myers J.E., Kenny L.C., McCowan L.M., Chan E.H., Dekker G.A., Poston L. et al.; SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. Br. J. Obstet. Gynaecol. 2013; 120(10): 1215-23.
  30. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003; 111(5): 707-16.
  31. Wathén K.A., Tuutti E., Stenman U.H., Alfthan H., Halmesmäki E., Finne P. et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 2006; 91(1): 180-4.
  32. De Vivo A., Baviera G., Giordano D., Todarello G., Corrado F., Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet. Gynecol. Scand. 2008; 87(8): 837-42.
  33. Maharaj A.S., Walshe T.E., Saint-Geniez M., Venkatesha S., Maldonado A.E., Himes N.C. et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J. Exp. Med. 2008; 205(2): 491-501.
  34. Wortelboer E.J., Koster M.P., Cuckle H.S., Stoutenbeek P.H., Schielen P.C., Visser G.H. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. Br. J. Obstet. Gynaecol. 2010; 117(11): 1384-9.
  35. Audibert F., Boucoiran I., An N., Aleksandrov N., Delvin E., Bujold E., Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am. J. Obstet. Gynecol. 2010; 203(4): 383. e1-8.
  36. Odibo A.O., Zhong Y., Goetzinger K.R., Odibo L., Bick J.L., Bower C.R., Nelson D.M. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011; 32(8): 598-602.
  37. Cnossen J.S., Morris R.K., ter Riet G., Mol B.W., van der Post J.A., Coomarasamy A. et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. Can. Med. Assoc. J. 2008; 178(6): 701-11.
  38. Pilalis A., Souka A.P., Antsaklis P., Basayiannis K., Benardis P., Haidopoulos D. et al. Screening for pre-eclampsia and small for gestational age fetuses at the 11-14 weeks scan by uterine artery Dopplers. Acta Obstet. Gynecol. Scand. 2007; 86(5): 530-4.
  39. Afrakhteh M., Moeini A., Taheri M.S., Haghighatkhah H.R., Fakhri M., Masoom N. Uterine Doppler velocimetry of the uterine arteries in the second and third trimesters for the prediction of gestational outcome. Rev. Bras. Ginecol. Obstet. 2014; 36(1): 35-9.
  40. Краснопольский В.И., Титченко Л.И., Туманова В.А., Петрухин В.А., Чечнева М.А., Пырсикова Ж.Ю. Возможности использования трехмерной допплерометрии для исследования внутриплацентарного кровотока у беременных с высоким риском развития перинатальной патологии. Российский вестник акушера-гинеколога. 2003; 3: 24-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies